NeuroMetrix develops and commercializes health care products that utilize non-invasive neurostimulation. Co. designs, builds and markets medical devices that stimulate nerves and analyzes nerve response for diagnostic and therapeutic purposes. Co.'s products consist of a medical device used in conjunction with a consumable electrode or biosensor. Co.'s marketed products include: DPNCheck, which is a nerve conduction test that is used to evaluate evaluate peripheral neuropathies such as diabetic peripheral neuropathy; Quell, which is a wearable device for symptomatic relief of chronic pain; and ADVANCE System, which is a platform for the performance of nerve conduction studies. The NURO stock yearly return is shown above.
The yearly return on the NURO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NURO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|